Bank of America
IMVT icon

Bank of America’s Immunovant IMVT Stock Holding History

Bank of America’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.2M Buy
893,678
+580,197
+185% +$15M ﹤0.01% 2289
2025
Q4 		$7.97M Sell
313,481
-61,288
-16% -$1.37M ﹤0.01% 3016
2025
Q3 		$6.04M Sell
374,769
-46,957
-11% -$760K ﹤0.01% 3809
2025
Q2 		$6.75M Sell
421,726
-50,235
-11% -$760K ﹤0.01% 3585
2025
Q1 		$8.07M Buy
471,961
+130,426
+38% +$2.73M ﹤0.01% 3355
2024
Q4 		$8.46M Buy
341,535
+114,511
+50% +$3.25M ﹤0.01% 3113
2024
Q3 		$6.47M Sell
227,024
-16,310
-7% -$481K ﹤0.01% 3491
2024
Q2 		$6.42M Buy
243,334
+34,704
+17% +$987K ﹤0.01% 3386
2024
Q1 		$6.74M Sell
208,630
-13,746
-6% -$501K ﹤0.01% 3357
2023
Q4 		$9.37M Sell
222,376
-380,416
-63% -$14M ﹤0.01% 2958
2023
Q3 		$23.1M Buy
602,792
+425,932
+241% +$9.63M ﹤0.01% 1885
2023
Q2 		$3.36M Sell
176,860
-232,954
-57% -$4.34M ﹤0.01% 3759
2023
Q1 		$6.36M Buy
409,814
+175,011
+75% +$3.04M ﹤0.01% 3293
2022
Q4 		$4.17M Buy
234,803
+209,331
+822% +$2.64M ﹤0.01% 3560
2022
Q3 		$142K Buy
25,472
+11,048
+77% +$54K ﹤0.01% 6167
2022
Q2 		$56K Sell
14,424
-11,743
-45% -$50.7K ﹤0.01% 6777
2022
Q1 		$144K Sell
26,167
-199,281
-88% -$1.24M ﹤0.01% 6657
2021
Q4 		$1.92M Buy
225,448
+130,142
+137% +$1.07M ﹤0.01% 4605
2021
Q3 		$828K Sell
95,306
-39,415
-29% -$356K ﹤0.01% 5243
2021
Q2 		$1.43M Buy
134,721
+10,428
+8% +$146K ﹤0.01% 4612
2021
Q1 		$1.99M Buy
124,293
+97,425
+363% +$2.57M ﹤0.01% 4262
2020
Q4 		$1.24M Sell
26,868
-6,582
-20% -$304K ﹤0.01% 4318
2020
Q3 		$1.18M Buy
33,450
+21,453
+179% +$645K ﹤0.01% 4089
2020
Q2 		$292K Buy
11,997
+3,585
+43% +$76.8K ﹤0.01% 4995
2020
Q1 		$131K Buy
+8,412
New +$127K ﹤0.01% 5363

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bank of America's IMVT Position: Q1 2026 in Review

Bank of America increased its Immunovant (IMVT) stake by 185% in Q1 2026, buying an estimated $15M and bringing the position to 893,678 shares worth $22.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2289.

Bank of America first reported a position in IMVT in Q1 2020 and has held it in 25 quarters since. The position peaked at $23.1M in Q3 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Bank of America held 893,678 shares of Immunovant worth $22.2M as of Q1 2026.
  • Bank of America bought 580,197 Immunovant shares in Q1 2026, an estimated $15M.
  • Immunovant made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2289 holding.
  • Bank of America first reported a position in Immunovant in Q1 2020 and has held it in 25 quarters since.
  • Bank of America's Immunovant position peaked at $23.1M in Q3 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.